FDA's joint advisory committee voted (22-1) to keep GlaxoSmithKline's diabetes drug Avandia on the market with a black box warning for patients at higher cardiovascular risk. All the votes came with the caveat for stronger warnings.But they voted 20-3 that Avandia increases the cardiac ischemic risk in type 2 diabetes. What an odd vote.
We don't think it means very much and that Avandia, for all intents and purposes, is dead. See our previous post below. What do you all think?
This is an interesting story. An associate of mine is actually hosting a forum on medical ethics in San Francisco this November, highlighting the FDA's decision regarding Avandia. With all of the debate about the drug and it's implications, I’m curious to find out if there is any progress to be made in light of this news.
ReplyDelete